WHO ICTRP trial
Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab…
JPRN-UMIN000010227 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000010227 |
|---|---|
| Public title | Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin for HER2-positive operable breast cancer: KBOG-1204 trial |
| Scientific title | Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin for HER2-positive operable breast cancer: KBOG-1204 trial - Neoadjuvant TCbH therapy for HER2-positive breast cancer: KBOG-1204 trial |
| Primary sponsor | Kanagawa Breast Oncology Group (KBOG) |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | breast cancer |
| Interventions | Neoaduvant chemotherapy with Docetaxel+Carboplatin+Trastuzumab |
| Registration date | Dec 3, 2013 |
| Target size | 40 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: